Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Adding Nubeqa to Therapy May Reduce PSA Levels in Metastatic Hormone-Sensitive Prostate Cancer
May 1st 2023Men with metastatic hormone-sensitive prostate cancer treated with Nubeqa, androgen-deprivation therapy and docetaxel had reductions in PSA levels that were associated with improved overall survival and a prolonged time to PSA progression.